Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy
T. Wibmer, T. Berghmans, C. Kropf, J.J. Lafitte, K.M. Stoiber, M. Paesmans, S. Ruediger, A. Scherpereel, I. Blanta, W. Rottbauer, J.P. Sculier, C. Schumann (Ulm, Germany; Brussels, Belgium; Lille, France)
Source: Annual Congress 2012 - Treatment of lung cancer
Session: Treatment of lung cancer
Session type: Oral Presentation
Number: 3264
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Wibmer, T. Berghmans, C. Kropf, J.J. Lafitte, K.M. Stoiber, M. Paesmans, S. Ruediger, A. Scherpereel, I. Blanta, W. Rottbauer, J.P. Sculier, C. Schumann (Ulm, Germany; Brussels, Belgium; Lille, France). Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy. Eur Respir J 2012; 40: Suppl. 56, 3264
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002
Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001
Vinorelbin and cisplatin in the treatment of advanced stage non-small cell lung cancer: Indian experience Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003
Low dosage chemotherapy, with carboplatin (CBDCA) and vinorelbine (VNR), in advanced nonsmall cell lung cancer (NSCLC) in patients with low performance status Source: Eur Respir J 2003; 22: Suppl. 45, 528s Year: 2003
Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study Source: Eur Respir J 2003; 22: Suppl. 45, 28s Year: 2003
Chemotherapy with carboplatin and gemcitabine in patients with non resectable stages of non-small cell lung cancer (non-SCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 436s Year: 2007
Treatment of advanced non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005
The comparison of paclitaxel-carboplatin (PCp) versus gemcitabine-cisplatin (GC) in the treatment of locally advanced or metastatic non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007
Locally advanced inoperable non-small cell lung cancer (NSCLC) treated by weekly paclitaxel/carboplatin chemotherapy with concomitant radiotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 433s Year: 2007
Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006
Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003
Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018